News & Events
Read more VitroScan and Radboudumc join forces to advance novel cell therapy for ovarian cancer patients
26 May 2026
We are proud to announce the launch of the EXACCT project, a new collaboration between VitroScan and Radboudumc focused on advancing innovative CAR-NK cell therapies for ovarian cancer patients.
Read more
Read more Meet VitroScan at BIO2026!
11 May 2026
VitroScan will be at BIO2026 in San Diego, June 22–25. We look forward to connecting with partners to discuss how our ex vivo micro-tumor testing platform can help de-risk and accelerate oncology drug development by generating clinically relevant efficacy insights earlier in the process.
Read more
Read more VitroScan presented twice at the AACR2026 annual meeting
22 April 2026
Proud to see our very own Felix Behr, PhD presenting twice at the recent #AACR2026 annual meeting with both an oral and a poster presentation showcasing how our ex vivo micro-tumor platform can help characterize and predict patient-specific responses to ADCs and immunotherapies.
Read more
Read more VitroScan has been awarded an Innovation Voucher from the Leiden Bio Science Park!
13 April 2026
We’re proud to share that VitroScan has been awarded an Innovation Voucher from the Leiden Bio Science Park! This support enables us to continue to invest in state-of-the-art laboratory infrastructure in our central lab at BioPartner Leiden, which is an important step in accelerating our technology development and bringing impactful testing for cancer patients another step closer to clinical practice.
Read more
Read more Esmee Koedoot Presents VitroScan’s Approach to Precision Oncology at LBSP TechTalk
17 March 2026
VitroScan presented at the March TechTalk at Leiden Bio Science Park, where Esmee Koedoot shared how the company is advancing precision oncology through predictive, patient-specific insights that support therapy selection to improve patient outcomes. The event brought together a diverse group of innovators from across the life sciences ecosystem, fostering valuable discussions and knowledge exchange.
Read more
Read more VitroScan Shares ChemoPredict Journey at Biotech Booster Annual Event
11 March 2026
CEO Willemijn Vader and PSC Chair Joris Schuurmans highlighted lessons learned in the ChemoPredict Biotech Booster project from scientific innovation towards a market-ready solution.
Read more
Read more A Major Milestone for VitroScan: ISO 15189 Compliance! 🎉
10 March 2026
As of March 2026, VitroScan is operating under an ISO 15189 compliant quality management system. This internationally recognized quality standard sets the benchmark for excellence in medical laboratories, ensuring that every clinical sample analysis meets the highest levels of quality, reliability, and regulatory compliance.
Read more
Read more Biotech Booster Annual Event 2026 on March 10: Willemijn Vader and Joris Schuurmans will present ChemoPredict project journey
5 February 2026
Join Willemijn Vader, CEO at VitroScan, and Joris Schuurmans, Chair of the ChemoPredict project steering committee, at the Biotech Booster Annual Event on March 10.
Read more
Read more Meet VitroScan!
1 November 2025
In this video, Willemijn Vader explains how our ChemoPredict platform supports better treatment decisions.
Read more
Read more VitroScan awarded Kansen voor West grant to advance ex vivo tumor testing for next-generation immunotherapies
29 October 2025
VitroScan awarded 'Kansen voor West'-grant to advance ex vivo tumor testing for next-generation immunotherapies
Read more
Read more VitroScan's micro-tumor test accurately predicts chemotherapy response for ovarian cancer patients
9 September 2025
VitroScan is proud to announce the publication of a study showing its 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.
Read more
Read more VitroScan awarded €1.9M by Biotech Booster to deliver chemotherapy response prediction for ovarian cancer patients
25 November 2024
VitroScan has developed ChemoPredict™, a predictive tumor testing service that revolutionizes treatment options for ovarian cancer patients.
Read more